REG - Ergomed plc - Notice of AGM and Annual Report

ErgomedAnnouncement

17/05/2019 07:05

RNS Number : 3415Z
Ergomed plc
17 May 2019
 


 PRESS RELEASE
 
 
Notice of AGM and Annual Report
 
Guildford, UK - 17 May 2019: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that it will host its Annual General Meeting at the offices of Covington & Burling LLP, 265 Strand, London WC2R 1BH at 9:30 a.m. on Tuesday 18 June 2019.
Ergomed's Annual Report and Accounts for the year ended 31 December 2018, Notice of AGM and Form of Proxy will be available on the Company's website at www.ergomedplc.com and are being mailed to its shareholders today.
 
Enquiries:
 



Ergomed plc


 Tel: +44 (0) 1483 402 975




Miroslav Reljanović (Executive Chairman)








Stuart Jackson (Chief Financial Officer)


















Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Freddie Barnfield / Huw Jeremy (Nominated Adviser)








James Black (Broker)


















Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Mary-Jane Elliott


ergomed@consilium-comms.com




Matthew Neal / Olivia Manser


















MC Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke







 
 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NOACKADQBBKBQPD